Document is current
Any future updates will be listed below
-
Authors
Awaki, Etsuko
Takeshima, Takao
Matsumori, Yasuhiko
Hirata, Koichi
Miyazaki, Naoki https://orcid.org/0000-0001-7753-5191
Takemura, Ryo https://orcid.org/0000-0002-3733-7411
Osaga, Satoshi https://orcid.org/0000-0003-4459-2469
Tanizawa, Yoshinori https://orcid.org/0000-0002-5014-2483
Komori, Mika https://orcid.org/0000-0003-1887-1296
-
Funding
Funding for this research was provided by:
Eli Lilly and Company (Study funding)
Eli Lilly Japan (Funding for analysis, medical writing, publication fees)
Daiichi-Sankyo (Funding for medical writing)
- License Information
-
More Information
Article History
Received: 15 August 2023
Accepted: 22 November 2023
First Online: 4 January 2024
Declarations
:
: Etsuko Awaki reports lecture fees/honoraria from Amgen, Daiichi Sankyo Company, Limited, Eli Lilly Japan K.K., and Otsuka Pharmaceutical Co., Ltd. Takao Takeshima received research funding/collaborative research expenses from Biohaven, Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Lundbeck Japan K.K., and Shionogi & Co., Ltd., and reports personal fees from Amgen Astellas BioPharma K.K., Daiichi Sankyo Company, Limited, Eli Lilly Japan K.K., and Otsuka Pharmaceutical Co., Ltd. Takao Takeshima also acted as an advisor to Hedgehog MedTech, Inc. and Sawai Pharmaceutical Co., Ltd. Yasuhiko Matsumori reports personal consultancy fees from Amgen Astellas BioPharma K.K., Daiichi Sankyo Company, Limited, Eli Lilly Japan K.K., and Otsuka Pharmaceutical Co., Ltd. during the conduct of the study. Koichi Hirata received research funding from the Japanese Ministry of Health, Labour and Welfare and the Japan Agency for Medical Research and Development, and reports personal fees from AbbVie GK, Amgen Astellas BioPharma K.K., Daiichi Sankyo Company, Limited, Eisai Co., Ltd., Eli Lilly Japan K.K., MSD Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc., and Sawai Pharmaceutical Co., Ltd. Naoki Miyazaki and Ryo Takemura are employees of Keio University. Keio University received funding from Eli Lilly Japan K.K. for the statistical analyses reported in this manuscript. Satoshi Osaga, Yoshinori Tanizawa, and Mika Komori are employees of Eli Lilly Japan K.K. and own minor shares in Eli Lilly and Company.
: The study was granted ethical approval by the Research Institute of Healthcare Data Science Ethical Review Board (ID: RI2020003), and electronic informed consent was obtained from all respondents. All data were anonymized before analysis. This study was performed in accordance with the Helsinki Declaration of 1964, and its later amendments<b>.</b>
